Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
XOMA Corp (XOMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: XOMA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Year Target Price $64.67
Year Target Price $64.67
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.48% | Avg. Invested days 32 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 301.57M USD | Price to earnings Ratio - | 1Y Target Price 64.67 |
Price to earnings Ratio - | 1Y Target Price 64.67 | ||
Volume (30-day avg) 4 | Beta 0.94 | 52 Weeks Range 18.35 - 35.00 | Updated Date 06/30/2025 |
52 Weeks Range 18.35 - 35.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -6.66% | Operating Margin (TTM) 37.26% |
Management Effectiveness
Return on Assets (TTM) -6.78% | Return on Equity (TTM) -3.43% |
Valuation
Trailing PE - | Forward PE 90.09 | Enterprise Value 323359768 | Price to Sales(TTM) 7.03 |
Enterprise Value 323359768 | Price to Sales(TTM) 7.03 | ||
Enterprise Value to Revenue 24.78 | Enterprise Value to EBITDA 53.89 | Shares Outstanding 11966900 | Shares Floating 9237720 |
Shares Outstanding 11966900 | Shares Floating 9237720 | ||
Percent Insiders 0.94 | Percent Institutions 62.66 |
Analyst Ratings
Rating 2 | Target Price 64.67 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
XOMA Corp
Company Overview
History and Background
XOMA Corp is a biotechnology company focused on antibody discovery and development. Founded in 1981, it has evolved from developing its own pipeline to licensing its antibody technologies to other pharmaceutical companies. Significant milestones include the development of antibody discovery platforms and strategic collaborations.
Core Business Areas
- Antibody Discovery & Development: XOMA focuses on its innovative antibody discovery and development platforms. They license these technologies to pharmaceutical companies for the development of new therapies across various disease areas.
- Royalty & Milestone Revenue: XOMA generates revenue through royalties and milestone payments from its partnered programs. This business model allows for revenue generation without the financial burden of drug development.
Leadership and Structure
The leadership team consists of experienced professionals in biotechnology and finance. The organizational structure is focused on licensing and managing existing partnerships, with a lean internal team.
Top Products and Market Share
Key Offerings
- Antibody Discovery Platforms: XOMA licenses its antibody discovery platforms, including technologies like XMetA, to other companies. Revenue is primarily derived from milestone payments and royalties. Competitors include companies with similar antibody discovery technologies, such as AbCellera (ABCL) and Ligand Pharmaceuticals (LGND).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high innovation, regulatory scrutiny, and long development timelines. Antibody therapies represent a significant portion of the market, with increasing demand for novel and effective treatments.
Positioning
XOMA is positioned as a licensor of antibody discovery technologies. Its competitive advantage lies in its established platform and track record of successful partnerships.
Total Addressable Market (TAM)
The global antibody therapeutics market is expected to reach hundreds of billions of dollars. XOMA is positioned to capture a portion of this TAM through licensing its technologies to companies developing new antibody drugs.
Upturn SWOT Analysis
Strengths
- Proprietary antibody discovery platforms
- Experienced management team
- Established partnerships with pharmaceutical companies
- Royalty and milestone revenue stream
- Lean operational structure
Weaknesses
- Dependence on partners for drug development
- Limited control over clinical trials and regulatory approvals
- Revenue stream dependent on partner success
- Small size compared to large pharmaceutical companies
Opportunities
- Expanding partnerships with new pharmaceutical companies
- Developing new and improved antibody discovery technologies
- Capitalizing on the growing demand for antibody therapies
- Potential for increased royalty revenue from successful partnered programs
Threats
- Failure of partnered programs in clinical trials
- Competition from other antibody discovery companies
- Changes in regulatory environment
- Economic downturn impacting pharmaceutical R&D spending
Competitors and Market Share
Key Competitors
- ABCL
- LGND
- CRIS
Competitive Landscape
XOMA competes with other biotechnology companies offering antibody discovery technologies. Its advantages include its established platform and experienced team. Disadvantages include its smaller size and dependence on partners.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the signing of new partnerships and the achievement of milestones in existing programs.
Future Projections: Future growth is projected to be driven by the expansion of the partnership network and the successful development of partnered antibody therapies.
Recent Initiatives: Recent initiatives include the development of new antibody discovery technologies and the pursuit of strategic collaborations.
Summary
XOMA Corp is a biotechnology company focusing on antibody discovery through licensing partnerships. Its performance depends on the success of its partners' drug development efforts. The company's strength lies in its proprietary technology and experienced team; however, it faces risks associated with reliance on partners. Future growth will depend on expanding partnerships and achieving milestones.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Company Website
- Third-party financial data providers
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About XOMA Corp
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 1989-04-05 | CEO & Director Mr. Owen P. Hughes Jr. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.xoma.com |
Full time employees 13 | Website https://www.xoma.com | ||
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.